Sarepta’s new CEO Michael Severino faces critical milestones to prove growth

In his first earnings call just days after becoming Sarepta Therapeutics | In his first earnings call just days after becoming Sarepta Therapeutics' CEO, Michael Severino recognized that the rare disease drugmaker faces multiple upcoming milestones to clarify its growth trajectory.

Raccontata dafiercepharma.com